Lactobacillus Or Pediococcus Or Leuconostoc Patents (Class 424/93.45)
  • Patent number: 10842831
    Abstract: The present disclosure provides methods, systems, compositions, and kits to address the need for microbiome-related treatment of health conditions and disease. The present disclosure provides for treatment of metabolic conditions using microbial compositions.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: November 24, 2020
    Assignee: Pendulum Therapeutics, Inc.
    Inventors: Colleen Cutcliffe, John S. Eid, James H. Bullard, Marcus F. Schicklberger
  • Patent number: 10842832
    Abstract: The invention features the use of a defined microbial consortia for the replacement of a gut microbiome associated with disease. In particular, the invention provides for the treatment of hyperammonemia, Clostridium difficile colitis, hepatic encephalopathy associated with cirrhosis, and inflammatory bowel disease.
    Type: Grant
    Filed: August 28, 2018
    Date of Patent: November 24, 2020
    Assignee: The Trustees of The University Of Pennsylvania
    Inventors: Frederic Bushman, Gary Wu, James Lewis, Mark Goulian
  • Patent number: 10779550
    Abstract: A nutritional composition comprising at least one human milk oligosaccharide selected from 6? sialyllactose, lacto-N-neotetraose, lacto-N-tetraose, disialylated lacto-N-tetraose, 3?-fucosyllactose, and 3?-sialyllactose. The nutritional composition is used in a method of reducing stress in an individual in need thereof.
    Type: Grant
    Filed: December 18, 2013
    Date of Patent: September 22, 2020
    Inventors: Jomay Chow, Matthew Panasevich
  • Patent number: 10780135
    Abstract: A composition of probiotics is provided which promotes weight loss and maintenance thereof. More particularly, a probiotic mixture of Lactobacillus gasseri, Lactobacillus fermentum, and Lactobacillus rhamnosus are provided to reduce body adiposity, decrease inflammation of adipose tissue, and enhance metabolism in optional combination with prebiotics and excipients such as flow agents and binders. A method of administering the probiotic composition to an individual user is also provided.
    Type: Grant
    Filed: April 5, 2018
    Date of Patent: September 22, 2020
    Inventor: Hooman M. Melamed
  • Patent number: 10780137
    Abstract: The present invention relates to compositions comprising at least about 8% ?-glucans and/or at least about 8% ?-fucans, which has a prebiotic effect and act as a replacement for in-feed antibiotics. The present invention also relates to extraction methods to obtain such extracts and various uses for the compositions comprising ?-glucans and/or ?-fucans.
    Type: Grant
    Filed: July 8, 2019
    Date of Patent: September 22, 2020
    Assignee: Bioatlantis Limited
    Inventors: John O'Doherty, John T. O'Sullivan
  • Patent number: 10758555
    Abstract: The present invention relates to a composition comprising at least one fucosylated oligosaccharide, for use in preventing allergies and/or treating allergies and/or reducing the occurrence or the risk of allergies in an infant or a young child born from a mother deficient in at least one fucosylated oligosaccharide(s) or fed with a mother's milk deficient in at least one fucosylated oligosaccharide(s). The use of said composition in infant formula, milk fortifier or children's food is foreseen.
    Type: Grant
    Filed: November 4, 2014
    Date of Patent: September 1, 2020
    Assignee: Societe des Produits Nestle S.A.
    Inventors: Dominique Brassart, Clemens Kunz, Norbert Sprenger
  • Patent number: 10729804
    Abstract: The present invention relates to the use of nanofibrillar cellulose hydrogel in cell culture and medical applications. The invention relates to a composition comprising nanofibrillar cellulose, cross linkable polymer and at least one bioactive agent. The invention also provides methods for producing the composition and uses thereof. The present invention further relates to the use of said composition for manufacturing of a shaped matrix, the method of preparing said matrix, the matrix and the use of said matrix in various applications.
    Type: Grant
    Filed: February 10, 2016
    Date of Patent: August 4, 2020
    Inventors: Marjo Yliperttula, Patrick Lauren, Petter Somersalo, Yanru Lou
  • Patent number: 10716817
    Abstract: Molecules secreted or derived from probiotic bacteria are provided for use in compositions and methods for the treatment and/or prevention of infection by pathogenic viruses. The isolated secreted molecules can also be used in nutritional or medical food products which provide probiotics to the gastrointestinal tract of a mammal.
    Type: Grant
    Filed: December 8, 2017
    Date of Patent: July 21, 2020
    Inventor: Mansel Griffiths
  • Patent number: 10675311
    Abstract: This invention provides lactic acid bacteria that have one or more effects selected from among fatigue-ameliorating effect, blood circulation-improving effect, stool odor-reducing effect, and growth-promoting effect and that can be used with high safety. This invention further provides a pharmaceutical preparation comprising, as an active ingredient, lactic acid bacteria that have one or more effects selected from among fatigue-ameliorating effect, blood circulation-improving effect, stool odor-reducing effect, and growth-promoting effect. According to the invention, novel lactic acid bacteria belonging to the Enterococcus faecium species having particular mycological properties and exhibiting viability of 40% or higher when freeze-dried in the absence of a dispersion medium and viability of 80% or higher in a probiotic preparation when stored at 40° C.
    Type: Grant
    Filed: July 7, 2016
    Date of Patent: June 9, 2020
    Inventors: Airo Tategaki, Taizo Kawabe, Hozumi Tanaka
  • Patent number: 10668118
    Abstract: Provided herein are, inter alia, microbial compositions and methods of using the same. The microbial compositions provided include, inter alia, therapeutically effective amounts of Lactobacillus johnsonii, Faecalibacterium prausnitzii, Akkermansia muciniphila, Myxococcus xanthus and Pediococcus pentosaceus and are particularly useful for methods of treating and preventing inflammatory diseases.
    Type: Grant
    Filed: April 5, 2018
    Date of Patent: June 2, 2020
    Assignee: The Regents of the University of California
    Inventors: Susan Lynch, Nikole Kimes, Din Lin, Ricardo Valladares, Kei Fujimura
  • Patent number: 10660857
    Abstract: The disclosure provides an oral composition for reducing serum cholesterol, serum lipids, body fat, or atherogenic index or for prophylaxis or treatment of atherosclerosis, cardiovascular or cerebrovascular diseases, comprising a highly bsh active bacteria, isolate or supernatant thereof; wherein the highly bsh active bacteria degrades >50 ?mol glycodeoxycholic acid (GDCA)/gram/hour and >2 ?mol taurodeoxycholic acid (TDCA)/gram/hour when measured over 1 hour and 5 hours, respectively, or degrades >65 ?mol GDCA/g/hr and >7 ?mol TDCA/g/hr when measured over 30 minutes.
    Type: Grant
    Filed: May 19, 2011
    Date of Patent: May 26, 2020
    Assignee: UAS Laboratories LLC
    Inventors: Satya Prakash, Mitchell Lawrence Jones, Christopher Martoni
  • Patent number: 10646522
    Abstract: The present invention is related to a Lactobacillus strain, composition and use thereof for treating autoimmune disease and related complications. The composition comprises at least one isolate of Lactobacillus paracasei strain GMNL-32, L. reuteri strain GMNL-89 or L. reuteri strain GMNL-263, and a pharmaceutical carrier, for treating syndromes and related complications of the autoimmune diseases.
    Type: Grant
    Filed: April 16, 2018
    Date of Patent: May 12, 2020
    Assignee: GenMont Biotech Incorporation
    Inventors: Chih-Yang Huang, Wei-Wen Kuo, Bor-Show Tzang, Yi-Hsing Chen
  • Patent number: 10632156
    Abstract: The invention relates to methods of differentiation, isolation, propagation, and storage of small colony variants (SCVs) of E. coli, preferably E. coli 83972 or E. coli HU2117, or modified or variant forms thereof, and methods for using the prepared SCV bacteria to establish probiotic biofilms in treated subjects and/or on treated medical devices.
    Type: Grant
    Filed: March 27, 2015
    Date of Patent: April 28, 2020
    Assignee: Atterx Biotherapeutics, Inc.
    Inventors: Steven R. Watt, Caleb W. Dorsey, Joshua A. Smith
  • Patent number: 10597427
    Abstract: The present invention provides a diabetes-inducing bacterium and use thereof, and a reagent and a detection method for detecting the bacterium. According to the present invention, enteric colonization of the diabetes-inducing bacterium can be prevented, and diabetes can be treated and/or prevented.
    Type: Grant
    Filed: September 26, 2014
    Date of Patent: March 24, 2020
    Assignee: AJINOMOTO CO., INC.
    Inventors: Keishi Kameyama, Kikuji Itoh
  • Patent number: 10596208
    Abstract: The present invention provides a pharmaceutical composition and a food composition for preventing or treating lipid-related metabolic disease, which contain, as active ingredients, probiotics and a vitamin B complex. When the composition comprising the probiotics and the vitamin B complex is used, it may further promote in vivo absorption of the vitamin B complex, and may induce a synergistic effect on a reduction in blood lipid levels, thereby exhibiting an effect on the alleviation, prevention or treatment of obesity and lipid-related metabolic disease.
    Type: Grant
    Filed: November 2, 2017
    Date of Patent: March 24, 2020
    Assignee: Cell Biotech Co., Ltd.
    Inventor: Myung Jun Chung
  • Patent number: 10548928
    Abstract: The present invention provides the use of Lactobacillus paracasei, for maintaining or increasing the intestinal microbiota diversity in a subject having dysbiosis.
    Type: Grant
    Filed: April 15, 2015
    Date of Patent: February 4, 2020
    Inventors: Gianfranco Grompone, Muriel Derrien, Johan Van Hylckama Vlieg, Pascale Serror, Lionel Rigottier-Gois, Laureen Crouzet, Claire Cherbuy
  • Patent number: 10532050
    Abstract: The invention relates to a pharmaceutical composition comprising a protein phosphatase 2A (PP2A) inhibitor and monosodium glutamate.
    Type: Grant
    Filed: April 8, 2014
    Date of Patent: January 14, 2020
    Assignee: Lixte Biotechnology, Inc.
    Inventors: John S. Kovach, Mickey L. Wells
  • Patent number: 10487305
    Abstract: The present invention relates to food-grade bacteria and methods for removing toxic compounds, including lead, cadmium, mercury, arsenic and pesticides, from contaminated environments or substances.
    Type: Grant
    Filed: April 5, 2013
    Date of Patent: November 26, 2019
    Inventors: Jordan Bisanz, Gregor Reid, Marc Monachese, Johan Van Hylckama Vlieg, Tamara Smokvina, Jeremy Burton
  • Patent number: 10463704
    Abstract: The present invention relates to strain of Lactobacilli and compositions containing the strain for use in modifying the absorption of cholesterol in an individual or the treatment of heart disease, diabetes or obesity.
    Type: Grant
    Filed: November 5, 2014
    Date of Patent: November 5, 2019
    Inventor: Stephen Patrick O'Hara
  • Patent number: 10456428
    Abstract: A method and a composition having the Lactobacillus paracasei strain GMNL-653 for treating psoriasis is provided. The Lactobacillus paracasei strain GMNL-653 has anti-inflammation properties, and inhibits the secretion of cytokine IL-6 and IL-17, so that the psoriasis symptoms caused by over-inflammation are improved/relieved.
    Type: Grant
    Filed: August 14, 2017
    Date of Patent: October 29, 2019
    Inventors: Yi-Hsing Chen, Wan-Hua Tsai, Chia-Hsuan Chou, Pei-Jane Tsai, Tsuei Yin Huang
  • Patent number: 10420807
    Abstract: The invention relates to a new strain of Lactobacillus salivarius, products containing the new strain, the use thereof in and methods for the treatment and/or prevention of inflammation and/or infection in breast or udder tissue, particularly in a mammary gland of a human female. The inflammation and/or infection is preferably mastitis.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: September 24, 2019
    Assignee: N.V. NUTRICIA
    Inventors: Rocio Martin, Jan Knol, Leonides Fernández Álvarez, Irene Espinosa Martos, Esther Antonia Jiménez Quintana, Juan Miguel Rodríguez Gómez
  • Patent number: 10350248
    Abstract: Provided are uses of Bacteroides in preparation of a medicament. The medicament is for use in treatment or prevention of obesity and obesity-related diseases. Also provided are a pharmaceutical composition, a medicament, a food product, and an animal feed that comprise Bacteroides, uses thereof in treatment or prevention of obesity and obesity-related diseases, and a method for treatment or prevention of obesity and obesity-related diseases.
    Type: Grant
    Filed: September 30, 2014
    Date of Patent: July 16, 2019
    Inventors: Guang Ning, Jie Hong, Weiqing Wang, Ruixin Liu, Jiqiu Wang
  • Patent number: 10299490
    Abstract: The invention provides a method for producing a soy milk fermentation product, comprising an enzyme treatment step of hydrolyzing soy milk with a peptide bond hydrolase to obtain a fermentation substrate, and a fermentation step of fermenting the fermentation substrate with lactic acid bacteria belonging to Lactobacillus brevis to obtain a fermentation product.
    Type: Grant
    Filed: March 18, 2013
    Date of Patent: May 28, 2019
    Assignee: Sapporo Holdings Limited
    Inventors: Norihiko Tsuchimoto, Yasukazu Nakakita, Hiroyuki Harashima
  • Patent number: 10286026
    Abstract: The invention covers a novel treatment strategy that considerably improves conventional probiotic treatments of inflammatory bowel diseases, irritable bowel syndrome and other gastrointestinal disorders. Both probiotic microorganisms and the carrier of the probiotic microorganisms in form of a fermented cereal gruel are used as treatment effectors. Phospholipids may also be an effecter. The novel treatment strategy is capable of removing the symptoms of inflammatory bowel diseases regardless of a mild, moderate or severe stage of the disease.
    Type: Grant
    Filed: February 15, 2017
    Date of Patent: May 14, 2019
    Inventor: Hans Israelsen
  • Patent number: 10272100
    Abstract: Disclosed is a non-reducing end unsaturated mannuronic acid oligosaccharide having a molecular weight of 100-3000 Da, which is obtained by lysing polymannuronate as a substrate with alginate lyase, and provided are: a non-reducing end unsaturated mannuronic acid oligosaccharide; and pharmaceutical compositions for alleviating, preventing, or treating obesity, diabetes, and climacteric syndrome, and probiotics for promoting intestinal beneficial bacteria, the compositions and probiotics containing, as an active ingredient, the non-reducing end unsaturated mannuronic acid oligosaccharide, so that the antiobesity and antidiabetic effects, estrogen activity, and intestinal microflora controlling effect of the non-reducing end unsaturated mannuronic acid oligosaccharides are remarkably excellent as compared with non-reducing end saturated mannuronic acid oligosaccharides.
    Type: Grant
    Filed: August 15, 2017
    Date of Patent: April 30, 2019
    Inventor: Du Woon Kim
  • Patent number: 10265350
    Abstract: The invention relates to products and compositions that may be beneficial in animal husbandry. Said products and compositions comprise microorganisms, such as bacteria, and probiotic bacteria in particular. Thus, provided herein are microbial strains, as well as selection criteria which will enable the skilled reader to find further strains useful in the present invention. The strains, as well as compositions comprising the same, may be administered to animals, farmed animals such as swine in particular. The administration may occur in the first days of life. By administration of the products or compositions of the inventions animal growth can be promoted and animal weight can be increased. Bacterial infections may also be prevented or treated by said compounds or compositions.
    Type: Grant
    Filed: September 25, 2013
    Date of Patent: April 23, 2019
    Inventors: Pedro Miguel Rubio Nistal, Ana María Carvajal Urueña, Marta García Díez
  • Patent number: 10265351
    Abstract: Provided is a bacterial composition which comprises from 104 to 1012 cfu/g of Pediococcus pentosaceus cells which have the ability to induce the production of interleukin-10 to reduce inflammation in the intestinal tract among other features and is useful in the amelioration of excessive crying in infants.
    Type: Grant
    Filed: August 7, 2014
    Date of Patent: April 23, 2019
    Inventors: Jordi Cune Castellana, Elisabet Lazaro Mallen, Jordi Espadaler Mazo
  • Patent number: 10251914
    Abstract: The present invention provides compositions that include an extract of human feces, and methods for using such compositions, including methods for replacing or supplementing or modifying a subject's colon microbiota, and methods for treating a disease, pathological condition, and/or iatrogenic condition of the colon.
    Type: Grant
    Filed: June 19, 2017
    Date of Patent: April 9, 2019
    Assignee: Regents of the University of Minnesota
    Inventors: Michael J. Sadowsky, Alexander Khoruts, Alexa R. Weingarden, Matthew J. Hamilton
  • Patent number: 10245289
    Abstract: An embodiment is a method of preventing, mitigating or treating Lupus that includes administering an effective amount of a medicament to a human comprised of Lactobacillus bulgaricus B-30892 and/or a supernatant resulting from culturing Lactobacillus bulgaricus B-30892 and/or bioactive materials resulting from culturing Lactobacillus bulgaricus B-30892 to prevent, mitigate or treat Lupus.
    Type: Grant
    Filed: December 14, 2016
    Date of Patent: April 2, 2019
    Assignee: NuBiome, Inc.
    Inventor: Brian C. Lue
  • Patent number: 10245290
    Abstract: The present invention relates to at least one probiotic strain chosen from Lactobacillus paracasei, or at least one probiotic strain chosen from Lactobacillus paracaseiin combination with at least one probiotic strain chosen from Lactobacillus plantarum, for use in the treatment or prevention of osteoporosis or for use in increasing the absorption of at Ca2+ ions, in a mammal, preferably in a human.
    Type: Grant
    Filed: April 3, 2014
    Date of Patent: April 2, 2019
    Assignee: Probi AB
    Inventors: Anna Berggren, Niklas Larsson, Gunilla Önning, Irini Lazou Ahrén, Klara Sjögren, Claes Ohlsson
  • Patent number: 10238696
    Abstract: Lactic acid bacteria, which are isolated Lactococcus lactis subsp. lactis LL358 and isolated Lactobacillus salivarius LS159 respectively. By administering a composition comprising the lactic acid bacteria of the invention, renal injury, metabolic syndrome, hyperuricemia, hypocalcemia, and other disorders can be effectively ameliorated or treated.
    Type: Grant
    Filed: December 5, 2016
    Date of Patent: March 26, 2019
    Inventors: Chun-Chih Huang, Wen-Ying Huang, Hsueh Fang Wang, Paik Seong Lim, Pin Hsiu Liu
  • Patent number: 10238674
    Abstract: Oligosaccharides from bovine milk, whey and dairy products, and methods of producing bovine milk oligosaccharides are provided.
    Type: Grant
    Filed: July 20, 2017
    Date of Patent: March 26, 2019
    Assignee: The Regents of the University of California
    Inventors: J. Bruce German, David Mills, Carlito B. Lebrilla, Daniela Barile, Riccardo LoCascio
  • Patent number: 10232001
    Abstract: The present invention comprises a method for selecting lactic acid bacterial strains effective for preventing bone loss in humans and strains that have been selected according to the presented method. The selection method is based on the strain's capability of reestablishing an altered microbial community to normal and/or harboring at least one of four specific SNPs.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: March 19, 2019
    Assignees: BioGaia AB, Board of Trustees of Michigan State University
    Inventors: Eamonn Connolly, Robert Allen Britton, Laura Rae McCabe
  • Patent number: 10183046
    Abstract: A first aspect of the invention relates to a porcine lactic acid bacterial strain, wherein said bacterial strain is characterised by one or more of the following characteristics: (i) the ability to exhibit antimicrobial activity against E. coli; (ii) the ability to exhibit antimicrobial activity against S. enteritidis; (iii) the ability to suppress inflammation in IPEC cells induced by 12-0-tetradecaboylphorbol-13-acetate (PMA); (iv) the ability to block the attachment or invasion of IPEC cells by S. enteritidis; (v) the ability to block the attachment or invasion of IPEC cells by E. coli; (vi) the absence of antibiotic resistance to one or more antibiotics selected from the following: ampicillin; cefotaxime; chloramphenicol; erythromycin; gentamicin; tetracycline; vancomycin; metronizadole; nalidixic acid; and kanamycin; and (vii) the ability to exhibit heat stability when subjected to three cycles of heating, each cycle comprising heating at a temperature of 70° C. for a period of 15 minutes.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: January 22, 2019
    Assignee: 4D Pharma Research Limited
    Inventor: Denise Kelly
  • Patent number: 10174388
    Abstract: A method is provided for evaluating agents for the treatment of different intestinal motility disorders, using distinct methodological parts related to musculature and nerves of the GI tract which communicate with the brain. In particular, the present invention provides a method for the selection of an agent effective for the treatment of an intestinal motility disorder, wherein the method comprises: a) a step of spatiotemporal (ST) mapping carried out on a gastrointestinal segment to analyze the effect of the agent on gastrointestinal motility; and b) a step of ex vivo nerve bundle recording carried out on a gastrointestinal segment to analyze the effect of the agent on mesenteric afferent nerve firing. Bacterial strains selected by the methods of the invention and the use of the bacterial strains in the treatment of intestinal motility disorders are also provided.
    Type: Grant
    Filed: September 15, 2017
    Date of Patent: January 8, 2019
    Assignee: BioGaia AB
    Inventors: Eamonn Connolly, Wolfgang Kunze, John Bienenstock
  • Patent number: 10172793
    Abstract: A probiotic tablet comprising a probiotic micro-organism and other nutritionally active ingredients in two zones, a first zone comprising said probiotic micro-organism and prcicrably selenium, and a second zone comprising at least one said other active ingredient such as iron, other minerals and vitamin B6 kept separated from the probiotic micro-organism of said first zone, the water activity in said probiotic micro-organism containing first zone being no greater than 0.2 and the water content of said tablet being as much as 3% by weight. Good viability of the micro-organisms is obtained despite the relatively high overall moisture content.
    Type: Grant
    Filed: December 21, 2004
    Date of Patent: January 8, 2019
    Assignee: Ferrosan A.S.
    Inventors: Kristian Lund Henriksen, Helene Mathilda Mortensen, Marianne Winning
  • Patent number: 10166262
    Abstract: The invention is directed to a novel strain of Lactobacillus plantarum AMT14 and compositions comprising the same.
    Type: Grant
    Filed: April 20, 2017
    Date of Patent: January 1, 2019
    Inventors: Ewelina Sosnowska-Turek, Jaroslaw Piotr Turek
  • Patent number: 10159700
    Abstract: A composition of Lactobacillus fermentum GMNL-296 and a use of Lactobacillus fermentum GMNL-296 for producing a composition to improve the infection symptoms of Clostridium difficile are provided. The Lactobacillus fermentum GMNL-296 is to promote the expression of anti-inflammatory cytokine IL-10 and Treg cell related transcription factors, so that the infection symptoms of weight loss and intestinal abnormalities are improved.
    Type: Grant
    Filed: December 1, 2016
    Date of Patent: December 25, 2018
    Inventors: Yi-Hsing Chen, Wan-Hua Tsai
  • Patent number: 10149872
    Abstract: Provided is the new strain Lactobacillus pentosus CECT 7504 and compositions and products comprising said strain and uses in the prevention and/or treatment of candidiasis (oral, intestinal and vaginal) and of bacterial vaginosis.
    Type: Grant
    Filed: August 11, 2014
    Date of Patent: December 11, 2018
    Assignee: Gynea Laboratorios, S.L.
    Inventors: Jordi Espadaler Mazo, Miguel Angel Losada Diaz
  • Patent number: 10149869
    Abstract: The disclosure provides oral compositions and methods of using such compositions in treating subjects infected with one or more hepatic disorders. The compositions include lysates or cell wall extracts of one or more gram positive bacteria, exhibit particular activity against hepatitis C virus (HCV), and may be useful in treating those infected with HCV as well as other hepatic diseases or disorders. Also described are methods of treating a hepatic disease or disorder by administering a therapeutically effective amount of at least one therapeutically active agent capable of upregulating or downregulating the Complement system pathway, wherein the therapeutically active agent enhances the formation of one or more convertase enzymes.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: December 11, 2018
    Assignee: Labyrinth Holdings, LLC
    Inventor: Elizabeth McKenna
  • Patent number: 10124016
    Abstract: Disclosed is a nutritional composition comprising a combination of non-digestible oligosaccharides and a product obtained by incubating an aqueous substrate by bifidobacteria and optionally a product obtained by incubating an aqueous substrate by S. thermophilus. Said combination synergistically improves the immune system by stimulating the Th1 response, and/or decreasing the Th2 response, improving the vaccination response, improving the resistance against infections and/or decreasing allergy.
    Type: Grant
    Filed: January 13, 2017
    Date of Patent: November 13, 2018
    Assignee: N.V. NUTRICIA
    Inventors: Belinda Potappel-Van 'T Land, Leon Matthieu Johannes Knippels, Alma Jildou Nauta, Johan Garssen
  • Patent number: 10117832
    Abstract: Provided herein are methods and processes for emulsifying non-polar compounds, such as omega fatty acids. Also provided are compositions that can be prepared according to the methods and processes described herein. The compositions, for example, have a high amount of the non-polar compound, such as a large amount of omega fatty acids. The non-polar compounds are also present in very small droplets within composition. For example, the mean or median particle size of the droplets is less than about 5 ?m. Further, the composition includes a low amount of surfactant, such as less than about 10-15% of the surfactant.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: November 6, 2018
    Inventor: Peter Nguyen
  • Patent number: 10087241
    Abstract: This disclosure describes a fusion polypeptide that includes an anchor domain and a binding domain that specifically binds to a target biofilm. The anchor domain generally includes at least a portion of a cell membrane polypeptide. The binding domain includes a sufficient portion of a polypeptide that specifically binds to a component of a target biofilm to specifically bind to the target biofilm. This disclosure also describes cells that include the fusion polypeptide and methods involving the use of such cells.
    Type: Grant
    Filed: March 24, 2016
    Date of Patent: October 2, 2018
    Inventors: Christine Elizabeth Salomon, Joshua D. Erickson
  • Patent number: 10066233
    Abstract: The present invention relates to the use of one or more cas genes for modulating resistance in a cell against a target nucleic acid or a transcription product thereof.
    Type: Grant
    Filed: August 25, 2006
    Date of Patent: September 4, 2018
    Inventors: Rodolphe Barrangou, Patrick Boyaval, Christophe Fremaux, Philippe Horvath, Dennis Romero
  • Patent number: 10064902
    Abstract: The invention relates to a novel strain of Bifidobacterium animals ssp. animalis, which is able, inter alia, to improve the function of the enteric nervous system, and to compositions said novel strain.
    Type: Grant
    Filed: December 10, 2013
    Date of Patent: September 4, 2018
    Inventors: Sophie Legrain-Raspaud, Gianfranco Grompone, Sandrine Capronnier, Tamara Smokvina, Marie-Christine Degivry, Biliana Lesic, Michel Neunlist
  • Patent number: 10052354
    Abstract: It is to provide a composition derived from lactic acid bacteria having an anti-allergic effect (an effect of suppressing allergic symptoms such as hay fever) synergistically, and a food product, pet food, etc. containing the composition. It is to prepare a composition having an anti-allergic action, containing Lactobacillus crispatus KT-11 strain, KT-23 strain, or KT-25 strain bacterial cells and viable bacteria, dead bacteria, or a processed product of bacterial cells of other lactic acid bacteria belonging to the genus Lactobacillus, genus Bifidobacterium, genus Leuconostoc, genus Enterococcus, genus Pediococcus, etc. at a biomass-converted ratio of 99:1 to 50:50, preferably 99:1 to 75:25.
    Type: Grant
    Filed: March 4, 2011
    Date of Patent: August 21, 2018
    Assignee: KITII CO., LTD.
    Inventors: Keisuke Tobita, Hajime Otani
  • Patent number: 10028981
    Abstract: The present invention generally relates to the field of probiotic bacteria. In particular it relates to methods for treating functional GI disorders comprising administering Bifidobacterium longum, such as Bifidobacterium longum ATCC BAA-999.
    Type: Grant
    Filed: August 24, 2010
    Date of Patent: July 24, 2018
    Assignee: Nestec S.A.
    Inventors: Peter McLean, Gabriela Bergonzelli de Gonda, Stephen Michael Collins, Premysl Bercik, Elena Verdu de Bercik
  • Patent number: 10028983
    Abstract: Inoculation of ATM-deficient mice with probiotic microorganisms, such as L. johnsonii, changed immune parameters, decreased a marker of DNA damage and increased the lifespan of the mice. Compositions and methods described herein are useful for the treatment and prevention of Ataxia telangiectasia and other cancer-prone diseases, such as p53 deficiency-associated cancers. Compositions and methods of the present invention are also useful for treating and preventing radiation-induced toxicity to normal tissue in a subject being exposed to radiation. Compositions and methods of the invention can increase lifespan in a simple, non-invasive manner.
    Type: Grant
    Filed: February 19, 2014
    Date of Patent: July 24, 2018
    Assignee: The Regents of the University of California
    Inventors: Mitsuko L. Yamamoto, Robert H. Schiestl, Ramune Reliene, James Borneman, Laura L. Presley, Jonathan Braun
  • Patent number: 10022407
    Abstract: Provided are the use of Lactobacillus rhamnosus strain CNCM I-3690 for reducing diet-induced weight gain and/or diet-induced insulin resistance, and treating disorders resulting therefrom, such as overweight, obesity and obesity-related disorders in a subject.
    Type: Grant
    Filed: November 12, 2012
    Date of Patent: July 17, 2018
    Assignees: Compagnie Gervais Danone, Tufts University
    Inventors: Jian Shen, Jingjing Wang, Liping Zhao, Martin Saul Obin, Muriel Derrien, Emilie Rocher, Johan Van Hylckama Vlieg
  • Patent number: 10004771
    Abstract: The subject invention provides materials and methods that effectively support innate immunity and/or disperse pathogenic biofilms using readily available, nontoxic, natural substances, while supporting restoration of normal microbiotic homeostasis. In one embodiment, the subject invention provides anti-biofilm compositions comprising one or more probiotic organisms, anti-microbial honey, and other ingredients such as prebiotic compounds, other hive products, green tea derivatives, other plant derivatives, and vitamin D3.
    Type: Grant
    Filed: April 11, 2017
    Date of Patent: June 26, 2018
    Inventors: Eva A. Berkes, Nicholas T. Monsul, Frederick T. Boehm